- Home
- FT vs APLT Comparison
FT vs APLT Comparison
Compare FT & APLT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FT
- APLT
- Stock Information
- Founded
- FT 1988
- APLT 2016
- Country
- FT United States
- APLT United States
- Employees
- FT N/A
- APLT N/A
- Industry
- FT Trusts Except Educational Religious and Charitable
- APLT Biotechnology: Pharmaceutical Preparations
- Sector
- FT Finance
- APLT Health Care
- Exchange
- FT Nasdaq
- APLT Nasdaq
- Market Cap
- FT 199.8M
- APLT 178.6M
- IPO Year
- FT N/A
- APLT 2019
- Fundamental
- Price
- FT $8.01
- APLT $0.26
- Analyst Decision
- FT
- APLT Buy
- Analyst Count
- FT 0
- APLT 5
- Target Price
- FT N/A
- APLT $4.13
- AVG Volume (30 Days)
- FT 63.0K
- APLT 25.3M
- Earning Date
- FT 01-01-0001
- APLT 11-13-2025
- Dividend Yield
- FT 7.85%
- APLT N/A
- EPS Growth
- FT N/A
- APLT N/A
- EPS
- FT N/A
- APLT N/A
- Revenue
- FT N/A
- APLT $1,000,000.00
- Revenue This Year
- FT N/A
- APLT N/A
- Revenue Next Year
- FT N/A
- APLT $5,935.35
- P/E Ratio
- FT N/A
- APLT N/A
- Revenue Growth
- FT N/A
- APLT N/A
- 52 Week Low
- FT $5.97
- APLT $0.22
- 52 Week High
- FT $7.23
- APLT $10.48
- Technical
- Relative Strength Index (RSI)
- FT 50.59
- APLT 28.24
- Support Level
- FT $7.81
- APLT $0.25
- Resistance Level
- FT $8.00
- APLT $0.40
- Average True Range (ATR)
- FT 0.09
- APLT 0.10
- MACD
- FT -0.01
- APLT -0.04
- Stochastic Oscillator
- FT 53.41
- APLT 5.13
About FT Franklin Universal Trust
Franklin Universal Trust is a closed-end management investment company focused on providing high current income while preserving capital. Its secondary objective is to achieve income growth through dividend increases and capital appreciation. The fund invests in two asset classes: high-yield bonds and utility stocks. It applies fundamental research to build a diversified high-yield bond portfolio and targets utility companies with attractive dividend yields and a history of increasing dividends.
About APLT Applied Therapeutics Inc.
Applied Therapeutics Inc is a clinical-stage biopharmaceutical company, developing a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need. The company's drug compounds pipeline includes AT-007 which is a novel central nervous system, penetrant ARI that it is developing for the treatment of rare metabolic diseases, including Galactosemia and Sorbitol Dehydrogenase (SORD) Deficiency, AT-001 for the treatment of diabetic cardiomyopathy, and AT-003 for the treatment of diabetic retinopathy.